2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2166

Multimodal Edema Management After Total Knee Arthroplasty: A Pilot Study

Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Abstract Number: 2305

Multimorbidity May Worsen Fatigue in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: L02

Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2148

Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2144

Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2147

Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2160

Myopenia Is an Independent Risk Factor for Rotator Cuff Tear and Shoulder Dysfunction in Elderly People : Data from NAMGARAM Cohort

Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Abstract Number: 2588

Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1999

NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2049

National Estimates of Pain Medication Use in Patients with Osteoarthritis

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2316

National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2181

Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1989

Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2143

Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2046

NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis

SLE – Etiology & Pathogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].